Cargando…
Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624513/ https://www.ncbi.nlm.nih.gov/pubmed/36341992 http://dx.doi.org/10.1016/j.jinf.2022.10.030 |
| _version_ | 1784822248450818048 |
|---|---|
| author | Marcec, Robert Dodig, Vinko Michael Likic, Robert |
| author_facet | Marcec, Robert Dodig, Vinko Michael Likic, Robert |
| author_sort | Marcec, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9624513 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96245132022-11-02 Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? Marcec, Robert Dodig, Vinko Michael Likic, Robert J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2023-01 2022-11-01 /pmc/articles/PMC9624513/ /pubmed/36341992 http://dx.doi.org/10.1016/j.jinf.2022.10.030 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Marcec, Robert Dodig, Vinko Michael Likic, Robert Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title | Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title_full | Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title_fullStr | Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title_full_unstemmed | Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title_short | Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? |
| title_sort | regdanvimab improves disease mortality and morbidity in patients with covid-19: too optimistic and too early to say? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624513/ https://www.ncbi.nlm.nih.gov/pubmed/36341992 http://dx.doi.org/10.1016/j.jinf.2022.10.030 |
| work_keys_str_mv | AT marcecrobert regdanvimabimprovesdiseasemortalityandmorbidityinpatientswithcovid19toooptimisticandtooearlytosay AT dodigvinkomichael regdanvimabimprovesdiseasemortalityandmorbidityinpatientswithcovid19toooptimisticandtooearlytosay AT likicrobert regdanvimabimprovesdiseasemortalityandmorbidityinpatientswithcovid19toooptimisticandtooearlytosay |